Antares Pharma, Inc. (NASDAQ:ATRS) has been given a $5.00 price objective by stock analysts at HC Wainwright in a report released on Friday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 34.05% from the stock’s current price.

A number of other analysts have also weighed in on ATRS. Chardan Capital started coverage on shares of Antares Pharma in a research note on Friday, June 23rd. They issued a “buy” rating and a $5.00 price objective on the stock. Vetr lowered shares of Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 price target on the stock. in a research report on Monday, June 26th. Finally, Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Antares Pharma presently has a consensus rating of “Buy” and a consensus price target of $4.34.

Shares of Antares Pharma (NASDAQ ATRS) traded down 38.07% during midday trading on Friday, hitting $2.31. 7,631,162 shares of the stock were exchanged. The stock’s market cap is $361.30 million. Antares Pharma has a 12 month low of $1.41 and a 12 month high of $4.09. The firm’s 50-day moving average is $3.23 and its 200-day moving average is $3.01.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $13.42 million for the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. Equities research analysts predict that Antares Pharma will post ($0.11) earnings per share for the current year.

WARNING: “Antares Pharma, Inc. (ATRS) PT Set at $5.00 by HC Wainwright” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/13/antares-pharma-inc-atrs-given-buy-rating-at-hc-wainwright.html.

In other news, Director Thomas J. Garrity sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total value of $105,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. Company insiders own 11.60% of the company’s stock.

Several large investors have recently bought and sold shares of ATRS. Wells Fargo & Company MN raised its stake in Antares Pharma by 21.6% during the first quarter. Wells Fargo & Company MN now owns 767,600 shares of the specialty pharmaceutical company’s stock worth $2,180,000 after purchasing an additional 136,600 shares during the period. Bank of New York Mellon Corp increased its position in shares of Antares Pharma by 20.1% during the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock valued at $476,000 after acquiring an additional 28,029 shares during the last quarter. M&T Bank Corp acquired a new stake in shares of Antares Pharma during the first quarter valued at about $227,000. California Public Employees Retirement System increased its position in shares of Antares Pharma by 14.4% during the first quarter. California Public Employees Retirement System now owns 934,300 shares of the specialty pharmaceutical company’s stock valued at $2,653,000 after acquiring an additional 117,300 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Antares Pharma by 4.3% during the first quarter. Vanguard Group Inc. now owns 5,619,088 shares of the specialty pharmaceutical company’s stock valued at $15,958,000 after acquiring an additional 232,349 shares during the last quarter. 36.77% of the stock is currently owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.